Edgewise Therapeutics Inc

NASDAQ: EWTX
$18.33
-$1.67 (-8.4%)
Closing price May 10, 2024

EWTX Chart and Intraday Price

EWTX Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 3415 COLORADO AVE., BOULDER, CO, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 1,554.02M USD
Shares Outstanding 93,111,000
Edgewise Therapeutics is a biopharmaceutical firm focused on creating treatments for muscle disorders. Its flagship product, EDG-5506, is an oral medication currently in Phase II trials, aimed at treating dystrophinopathies such as Duchenne and Becker muscular dystrophy. The company is also working on EDG-7500 for severe cardiac disorders, now in Phase I trials. Additionally, Edgewise is developing a range of precision medicine candidates targeting specific muscle proteins to combat genetically defined muscle conditions. Founded in 2017, the company is based in Boulder, Colorado.

EWTX Articles

Huge Insider Buys From Warren Buffett, Jack Ma, Carlos Slim and More
Recent insider buying has been highlighted by purchases by Warren Buffett, Jack Ma, Carlos Slim, and John Paulson. Biotechs tempted insiders, as did public offerings.
Trey Thoelcke
Published: